<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538183</url>
  </required_header>
  <id_info>
    <org_study_id>DK-01/2017</org_study_id>
    <nct_id>NCT04538183</nct_id>
  </id_info>
  <brief_title>Use Test: Dermowas Body Lotion pH 4 vs. pH 5.8</brief_title>
  <official_title>Use Test: Dermowas Body Lotion pH 4 vs. pH 5.8</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. August Wolff GmbH &amp; Co. KG Arzneimittel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. August Wolff GmbH &amp; Co. KG Arzneimittel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study was to examine whether normalizing of the pH by acidification&#xD;
      through topical treatment helps to strengthen the skin barrier, to induce epidermal&#xD;
      differentiation and to reduce inflammation in healthy individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies have shown that an emollient adjusted to pH 4 has favorable effects to the&#xD;
      skin of aged individuals. The objective of the study was to examine whether normalizing of&#xD;
      the pH by acidification through topical treatment helps to strengthen the skin barrier, to&#xD;
      induce epidermal differentiation and to reduce Inflammation. The effect of a cosmetic&#xD;
      oil-in-water (O/W) emulsion adjusted to pH 4 in comparison to the same emulsion adjusted to&#xD;
      pH 5.8 on the integrity of the skin barrier and the mechanical stability was examined in&#xD;
      healthy volunteers from age 18 to 75 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">March 3, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Exploratory, Randomized, Double-blind (regarding the two test products), Intra-individual comparison</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The test areas were 5 x 5 cm squares on both inner (volar) forearms. The areas were randomized and double-blinded (regarding the two test products). For randomization, the permutated orthogonal Latin square method was used on condition that both test areas are always contralateral.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of transepidermal water loss (TEWL)</measure>
    <time_frame>Change from day 1 (before application) to day 30</time_frame>
    <description>Tewameter TM300, Courage &amp; Khazaka, Köln</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of skin hydration</measure>
    <time_frame>Change from day 1 (before application) to day 30</time_frame>
    <description>Corneometer CM 825, Courage &amp; Khazaka, Köln</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of erythema</measure>
    <time_frame>Change from Day 1 to day 30 + 2 hours (after tape-stripping), measured over 3 timepoints (Day 1, day 30 and day 30 +2 hours (after tape stripping)</time_frame>
    <description>Visible score adapted from Frosch and Kligman: 0 = no redness, 0.5 = very slight redness, 1 = slight patchy or diffuse redness, 2 = moderate even redness, 3 = profound redness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of pH</measure>
    <time_frame>Change from Baseline to day 31, measured over 5 time points (Day 1, day 30, day 30+3 hours, day 30+6 hours and day 31)</time_frame>
    <description>pH-Meter 910, Courage &amp; Khazaka, Köln</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tape-stripping</measure>
    <time_frame>Day 31</time_frame>
    <description>Number of the tape-strips until a threefold increase in TEWL compared to unstripped baseline value is reached. (D-Squame® (DSQ), CuDerm Corporation, Dallas)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneocyte size</measure>
    <time_frame>Day 31</time_frame>
    <description>After staining with Nile Red by immunofluorescence microscopy and digital imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of the cytokine IL-1α</measure>
    <time_frame>Day 31</time_frame>
    <description>Determined by enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of antimicrobial peptide hBD-2</measure>
    <time_frame>Day 31</time_frame>
    <description>Determined by enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>WO 5000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Body lotion pH 4 for topical application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WO 5001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Body lotion pH 5.8 for topical application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No product use</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated control area</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>WO 5000</intervention_name>
    <description>WO 5000</description>
    <arm_group_label>WO 5000</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>WO 5001</intervention_name>
    <description>WO 5001</description>
    <arm_group_label>WO 5001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female volunteers (75 % women and 25 % men)&#xD;
&#xD;
          -  Aged 18 - 75 years&#xD;
&#xD;
          -  Healthy skin&#xD;
&#xD;
          -  Informed consent was given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atopic diathesis, atopic dermatitis and other skin diseases with a disrupted skin&#xD;
             barrier&#xD;
&#xD;
          -  Dermatitis and other skin diseases in the test site&#xD;
&#xD;
          -  Birthmarks, tattoos, scars and other abnormalities in the test site, which may&#xD;
             influence the measurements&#xD;
&#xD;
          -  Women: pregnancy and breastfeeding&#xD;
&#xD;
          -  Known contact sensitization&#xD;
&#xD;
          -  Severe systemic diseases&#xD;
&#xD;
          -  Regular use of sauna and solarium&#xD;
&#xD;
          -  Intensive UV exposure&#xD;
&#xD;
          -  Topical use of drugs in the test site four weeks before and during the study&#xD;
&#xD;
          -  Systemic administration of anti-inflammatory, immune-modulating and antibiotic drugs&#xD;
&#xD;
          -  Previous participation in other studies within the last month before the study&#xD;
&#xD;
          -  Alcohol and drug misuse&#xD;
&#xD;
          -  Missing awareness and inability to follow the instructions of the study staff&#xD;
&#xD;
          -  Other reasons which according to the study leader speak against the participation in&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sören Merker, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Dr. August Wolff GmbH &amp; Co. KG Arzneimittel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Hautklinik Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

